Dr. Hönle AG revised earnings guidance for the year 2021/2022. The Management Board therefore expects sales of EUR 125 million to EUR 130 million and an operating loss (LBIT) of EUR 3 million to EUR 4 million for the Hönle Group in the 2021/2022 financial year. To date, the Executive Board has been expecting sales of between EUR 125 million and EUR 130 million (PY: EUR 115 million) and an operating result (EBIT) of between EUR 9 million and EUR 11 million (PY: EUR 0.3 million).
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
19.72 EUR | -0.63% | -0.25% | +12.00% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+12.00% | 130M | |
+14.20% | 86.04B | |
+18.36% | 36.93B | |
+24.23% | 34.44B | |
+8.61% | 27.97B | |
+5.22% | 27.27B | |
+7.43% | 27.11B | |
+21.55% | 26.56B | |
+19.44% | 25.25B | |
+20.50% | 18.53B |
- Stock Market
- Equities
- HNL Stock
- News Dr. Hönle AG
- Dr. Hönle AG Revises Earnings Guidance for the Year 2021/2022